Discontinue use if severe/persistent HTN or hypertensive crisis occurs; GI perforations or fistulas, acute MI, other clinically significant arterial thromboembolic complication or nephrotic syndrome develops; patients w/ reversible posterior leukoencephalopathy syndrome, wound healing complications requiring medical intervention. Interrupt or reduce dose, or discontinue use in case of persistent or recurrent significant GI disorders & biochemical laboratory test abnormalities. Not to be administered in patients who have or at risk for severe haemorrhage. Palmar-plantar erythrodysaesthesia syndrome (PPES); aneurysms & artery dissections. History of QT interval prolongation, patients taking antiarrhythmics or w/ pre-existing cardiac disease, bradycardia or electrolyte disturbances. Perform periodic monitoring w/ on-treatment ECG & electrolytes (serum Mg, K & Ca). Monitor for signs & symptoms of hepatic encephalopathy. Monitor urine protein regularly, platelet levels & biochemical parameters during treatment. Perform liver function tests prior to treatment. Discontinue use at least 28 days prior to scheduled surgery including dental surgery. Avoid chronic use of strong CYP3A4 inducers. Concomitant use w/ P-gp substrates (eg, fexofenadine, aliskiren, ambrisentan, dabigatran, etexilate, digoxin, colchicine, maraviroc, posaconazole, ranolazine, saxagliptin, sitagliptin, talinolol, tolvaptan), MRP2 (eg, cyclosporine, efavirenz, emtricitabine) & strong CYP3A4 inhibitors. Not to be used in patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Not recommended in severe renal & hepatic impairment (Child-Pugh C). Mild or moderate renal impairment. May impair male & female fertility. Women of childbearing potential & male partners should use effective contraception during & at least 4 mth after treatment. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr.